Current Status of Radiopharmaceutical Therapy

James, Sara St.; Bednarz, Bryan; Benedict, Stanley H; Buchsbaum, Jeffrey C.; Dewaraja, Yuni K.; Frey, Eric; Hobbs, R.; Grudzinski, Joseph; Roncali, Emilie; Sgouros, George; Capala, Jacek; Xiao, Ying

doi:10.1016/j.ijrobp.2020.08.035

Cited by 51 publications

(38 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Digestive system tumors are the most common tumor type and are associated with rapid malignant progression ( 1 ). Even after patients receive standard radiotherapy and chemotherapy treatment, the prognosis remains poor ( 2 , 3 ). This unsatisfactory prognosis is in part due to the hidden nature of digestive system tumors, making them difficult to detect early.…”

Section: Introductionmentioning

confidence: 99%

Re-Clustering and Profiling of Digestive System Tumors According to Microenvironment Components

Wang¹,

Guo²,

Chen³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundImmunotherapy has become the most promising therapy in digestive system tumors besides conventional chemotherapy and radiotherapy. But only a few patients can benefit from different types of immunotherapies, such as immune checkpoint blockade (ICB). To identify these ICB-susceptible patients, methods are urgently needed to screen and profile subgroups of patients with different responsiveness to ICB.MethodsThis study carried out analysis on patients with digestive system tumors that were obtained from Cancer Genome Atlas (TCGA) cohorts. The analyses were mainly performed using GraphPad Prism 7 and R language.ResultsWe have quantified the microenvironmental components of eight digestive system tumor patients in TCGA cohorts and evaluated their clinical value. We re-clustered patients based on their microenvironment composition and divided these patients into six clusters. The differences between these six clusters were profiled, including survival conditions, enriched biological processes, genomic mutations, and microenvironment traits. Cluster 3 was the most immune-related cluster, exhibiting a high infiltration of non-tumor components and poor survival status, along with an inhibitory immune status, and we found that patients with high stromal score indicated a poor response in ICB cohort.ConclusionsOur research provides a new strategy based on the microenvironment components for the reclassification of digestive system tumors, which could provide guidance for prognosis judgment and treatment response prediction like ICB.

show abstract

Section: Introductionmentioning

confidence: 99%

Re-Clustering and Profiling of Digestive System Tumors According to Microenvironment Components

Wang¹,

Guo²,

Chen³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Nuclear imaging of TK expression using Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) could therefore play an important role for subsequent TKI therapy [ 27 , 28 ]. Hence, non-invasive PET/SPECT imaging may be utilized to measure TK activity distribution in vivo, which in turn can be used to determine patient-specific treatment plans with calculated dosages to target and non-target organs (image-based dosimetry) [ 29 ]. Additionally, it can add a better understanding of the spatial RTK patterning in the very heterogeneous GB tumor microenvironment and allow for the longitudinal behavior of drugs (FDA-approved) to be studied in vivo [ 23 , 27 , 28 ].…”

Section: Nuclear Molecular Imaging and Trt Using Tkismentioning

confidence: 99%

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

et al. 2021

View full text Add to dashboard Cite

Glioblastoma (GB) remains the most fatal brain tumor characterized by a high infiltration rate and treatment resistance. Overexpression and/or mutation of receptor tyrosine kinases is common in GB, which subsequently leads to the activation of many downstream pathways that have a critical impact on tumor progression and therapy resistance. Therefore, receptor tyrosine kinase inhibitors (RTKIs) have been investigated to improve the dismal prognosis of GB in an effort to evolve into a personalized targeted therapy strategy with a better treatment outcome. Numerous RTKIs have been approved in the clinic and several radiopharmaceuticals are part of (pre)clinical trials as a non-invasive method to identify patients who could benefit from RTKI. The latter opens up the scope for theranostic applications. In this review, the present status of RTKIs for the treatment, nuclear imaging and targeted radionuclide therapy of GB is presented. The focus will be on seven tyrosine kinase receptors, based on their central role in GB: EGFR, VEGFR, MET, PDGFR, FGFR, Eph receptor and IGF1R. Finally, by way of analyzing structural and physiological characteristics of the TKIs with promising clinical trial results, four small molecule RTKIs were selected based on their potential to become new therapeutic GB radiopharmaceuticals.

show abstract

“…An individualized treatment plan, based on assessment of radiation doses delivered to the tumor and normal tissues and an understanding of the response of these tissues to the radiation dose deposited in them, is crucial to fully utilize the potential of RPT ( 22 ). It will also facilitate combination of RPT with other cancer treatment modalities such as immunotherapy, molecularly targeted therapies, and external beam radiotherapy.…”

Section: Physicsmentioning

confidence: 99%

Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care

Coleman¹,

Buchsbaum

Prasanna

et al. 2021

JNCI Cancer Spectrum

Self Cite

View full text Add to dashboard Cite

In a time of rapid advances in science and technology the opportunities for radiation oncology are undergoing transformational change. The linkage between and understanding of the physical dose and induced biological perturbations are opening entirely new areas of application. The ability to define anatomic extent of disease and the elucidation of the biology of metastases has brought a key role for radiation oncology for treating metastatic disease. That radiation can stimulate and suppress subpopulations of the immune response makes radiation a key participant in cancer immunotherapy. Targeted radiopharmaceutical therapy delivers radiation systemically with radionuclides and carrier molecules selected for their physical, chemical and biochemical properties. Radiation oncology usage of “big data” and machine learning/artificial intelligence adds the opportunity to markedly change the workflow for clinical practice while physically targeting and adapting radiation fields in real time. Future precision targeting requires multi-dimensional understanding of the imaging, underlying biology and anatomical relationship among tissues for radiation as spatial and temporal “focused biology”. Other means of energy delivery are available as are agents that can be activated by radiation with increasing ability to target treatments. With broad applicability of radiation in cancer treatment, it is a necessity for effective cancer care, opening a career path for global health serving the medically underserved in geographically isolated populations as a substantial societal contribution addressing health disparities. Understanding of risk and mitigation of radiation injury make it an important discipline for and beyond cancer care including energy policy, space exploration, national security and global partnerships.

show abstract

Current Status of Radiopharmaceutical Therapy

Cited by 51 publications

References 67 publications

Re-Clustering and Profiling of Digestive System Tumors According to Microenvironment Components

Re-Clustering and Profiling of Digestive System Tumors According to Microenvironment Components

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care

Contact Info

Product

Resources

About